Skip to main content

Giapreza FDA Approval History

Last updated by Judith Stewart, BPharm on March 2, 2021.

FDA Approved: Yes (First approved December 21, 2017)
Brand name: Giapreza
Generic name: angiotensin II
Dosage form: Injection
Previous Name: LJPC-501
Company: La Jolla Pharmaceutical Company
Treatment for: Hypotension, Shock

Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.

Development timeline for Giapreza

Dec 21, 2017Approval FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure
Aug 28, 2017La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.